Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cancer02:18

Cancer

54.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.4K
What is Cancer?02:12

What is Cancer?

14.4K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.4K
Cancer Prevention02:59

Cancer Prevention

8.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.1K
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.

Cell reports. Medicine·2026
Same author

The path forward for T cell engagers in patients with prostate cancer.

Journal for immunotherapy of cancer·2026
Same author

Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.

Cancer discovery·2024
Same author

Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer.

medRxiv : the preprint server for health sciences·2024
Same author

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same journal

The Biology of Malaria Parasite Liver Infection.

Cold Spring Harbor perspectives in medicine·2026
Same journal

The Interaction between Diabetes Mellitus and Tuberculosis: Epidemiology, Screening, and Clinical Management.

Cold Spring Harbor perspectives in medicine·2026
Same journal

New Malaria Prevention Modalities: Long-Acting Interventions Beyond Vaccines.

Cold Spring Harbor perspectives in medicine·2026
Same journal

From Parasite to Pill: Harnessing Biology for Breakthroughs in Antimalarial Drug Discovery.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Malaria Parasite Genomics: Decentralization, Diversification, and Development Goals.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Tuberculosis Infection: Diagnosis and Management.

Cold Spring Harbor perspectives in medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K

Immunotherapy for Prostate Cancer.

Nicholas J Venturini1, Charles G Drake1,2

  • 1Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032.

Cold Spring Harbor Perspectives in Medicine
|September 12, 2018
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors show limited success in prostate cancer treatment. Further research into the tumor microenvironment and immune response is needed for effective immunotherapy strategies.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

858

Related Experiment Videos

Last Updated: Feb 5, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

858

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors are effective cancer therapies for many tumor types.
  • Prostate cancer has not yet benefited from this treatment modality.

Purpose of the Study:

  • To evaluate the efficacy of immune checkpoint inhibitors in prostate cancer.
  • To identify reasons for the lack of response and explore future therapeutic strategies.

Main Methods:

  • Review of clinical trials evaluating immune checkpoint inhibitors in prostate cancer.
  • Analysis of combination strategies and their outcomes.

Main Results:

  • Several immune checkpoint inhibitors have been tested in prostate cancer, both as monotherapy and in combination.
  • While some combination strategies show potential, overall activity remains limited.

Conclusions:

  • Prostate cancer's lack of response to current immunotherapy is not due to insufficient testing.
  • Optimizing future treatment strategies requires a deeper understanding of the prostate cancer tumor microenvironment and its baseline immune status.